| Experiment ID | EXP00225 |
| Reference | Title: Biological and clinical relevance of miRNA expression signatures in primaryplasma cell leukemia. Author: Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T,Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A,Caravita T, Omede' P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. Journal: Clin Cancer Res. 2013 Jun 15;19(12):3130-42. doi: 10.1158/1078-0432.CCR-12-2043. Epub 2013 Apr 23. Abstract: PURPOSE: Primary plasma cell leukemia (pPCL) is a rare and very aggressive formof plasma cell dyscrasia. To date, no information on microRNA (miRNA) expression in pPCL has been reported. This study aimed at investigating the involvement ofmiRNAs in pPCL and their possible relationship with higher tumor aggressiveness.EXPERIMENTAL DESIGN: Global miRNA expression profiles were analyzed in highlypurified malignant plasma cells from 18 pPCL untreated patients included in aprospective clinical trial. MiRNA expression patterns were evaluated incomparison with a representative series of multiple myeloma patients, in relationto the most recurrent chromosomal abnormalities (as assessed by fluorescence insitu hybridization and single-nucleotide polymorphism-array analysis), and inassociation with clinical outcome. MiRNA expression was also integrated with geneexpression profiles in pPCL and multiple myeloma samples.RESULTS: We identified a series of deregulated miRNAs in pPCL (42 upregulated and41 downregulated) in comparison with multiple myeloma. Some of them, on the basisof their reported functions and putative target genes computed by integrativeanalysis, might have a role in the pathobiology of pPCL. As regards chromosomalaberrations, the expression of some miRNAs mapped to hotspot altered regions was associated with DNA copy number of the corresponding loci. Finally, 4 miRNA(miR-497, miR-106b, miR-181a*, and miR-181b) were identified as having expressionlevels that correlated with treatment response, and 4 (miR-92a, miR-330-3p,miR-22, and miR-146a) with clinical outcome.CONCLUSIONS: Overall, our study provides insights into the possible contribution of miRNAs in the pathogenesis of pPCL and suggests targets for future therapeuticinvestigations. PMID: 23613318 |
| Expressiion Profile | Description: Patterns of miRNA expression in primary plasma cell leukemias: implications for tumor progression in multiple myeloma Organism: Homo sapiens GEO ID: GSE37053 Platform: GPL8227 Number of samples: 57 |
| Design and Sample | Cancer Type: lymphoma Cancer SubType: multiple myeloma Cell Line: N/D Experimental Design: subtype1 vs substype2 Case Sample: multiple myeloma Control Sample: leukemia Num of Case: 39 Num of Control: 18 Quantification Software: Limma Num of miRNAs: 366 |
| Identification | Num of Up: 69 Num of Down: 66 |